American Renal Associates Holdings, Inc.
Join Class Action »
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of American Renal Associates Holdings, Inc. (NYSE: ARA) from August 10, 2016 through March 27, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover investor losses.
If you bought American Renal securities between August 10, 2016 and March 27, 2019 and would like an opportunity to recover your losses, please click “Join This Class Action,” above.
SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against American Renal Associates Holdings, Inc. – ARA
New York, N.Y., April 3, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of American Renal Associates Holdings, Inc. (NYSE: ARA) from August 10, 2016 through March 27, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for American Renal investors under the federal securities laws.
To join the American Renal class action, go to http://zhanginvestorlaw.com/cases/american-renal-a…tes-holdings-inc/ or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal’s accounting process for revenue recognition, collections, and related matters would give rise to an SEC investigation into the same, and increased regulatory scrutiny by the SEC; (2) American Renal’s financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018 were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/american-renal-a…tes-holdings-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang of Zhang Investor Law toll free at 800-991-3756 or via email at email@example.com.
Zhang Investor Law represents investors worldwide.